<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-361
Date of Submission: 2024-12-15

This report was submitted by a Other Healthcare Professional from Lee, Daniels and Miller Medical Center concerning patient ANON-PX-5391. The subject is a 52-year-old male with a significant medical history including migraines, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Topical route at a dosage of 188mg, initiated on 2024-09-29 for Gastroesophageal reflux disease and discontinued on 2024-11-27; Ibuprofen (NSAID) administered via the Oral route at a dosage of 405mg, initiated on 2024-09-29 for Pain and inflammation and discontinued on 2024-11-27.

On approximately 2024-11-23, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Hepatotoxicity. The Maculopapular Rash was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Not give position end media discover condition according. You real dinner.</data>
report_id: ADR-2024-361
report_date: '2024-12-15'
patient_details:
  patient_id: ANON-PX-5391
  gender: Male
  relevant_history:
  - migraines
  - type 2 diabetes
  age_at_reaction: 52
suspected_drugs:
- drug_name: Omeprazole
  dosage: 188mg
  route_of_administration: Topical
  start_date: '2024-09-29'
  indication_for_use: Gastroesophageal reflux disease
  drug_class: Proton-pump inhibitor
  end_date: '2024-11-27'
- drug_name: Ibuprofen
  dosage: 405mg
  route_of_administration: Oral
  start_date: '2024-09-29'
  indication_for_use: Pain and inflammation
  drug_class: NSAID
  end_date: '2024-11-27'
adverse_reactions:
- symptom_name: Maculopapular Rash
  onset_date: '2024-11-23'
  severity: Life-threatening
  outcome: Fatal
  intervention_required: true
- symptom_name: Hepatotoxicity
  onset_date: '2024-11-23'
  severity: Mild
  outcome: Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Highly Probable
  dechallenge_rechallenge: Rechallenge not performed
  naranjo_score: 10
reporting_facility: Lee, Daniels and Miller Medical Center
reporter_type: Other Healthcare Professional
notes: Not give position end media discover condition according. You real dinner.
